Skip to content

Oruka Therapeutics

US · ORKA #2003 by market cap Listed 1970
95.81 -1.76 -1.80%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 5.98 Expensive vs history 92nd percentile
5-year average 1.71 · #406 of 514 in Biotechnology
P/E ratio -49.69 Cheap vs history 17th percentile
5-year average -21.51 · forward -31.18
P/S ratio --
5-year average 0.00

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Oruka Therapeutics (ORKA) 6.50B -45.19 5.44 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value100.30 Economic moatNone UncertaintyVery High

Trading 4.7% below Morningstar's fair value estimate.

Fair value

Oruka Therapeutics Inc earns a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 5% premium over our quantitative fair value estimate of $100.30 per share; however, this estimate should be taken with a pinch of salt due to its very high uncertainty rating.

The firm's lack of profitability undermines our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of -1.5%, which lies in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The firm's liquidity is an additional cause for concern. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, falls in the top 40% compared with global peers. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. This characteristic further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:27 · For reference only, not investment advice and not tailored to your situation.

Oruka Therapeutics discussion 0 comments

Add a comment